A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis
A. Dierig, M. Hoelscher, S. Schultz, L. Hoffmann, A. Jarchow-MacDonald, E. M. Svensson, L. Te Brake, R. Aarnoutse, M. Boeree, T. D. McHugh, L. M. Wildner, X. Gong, P. P. J. Phillips, L. T. Minja, N. Ntinginya, S. Mpagama, A. Liyoyo, R. S. Wallis, M. Sebe, F. A. MhimbiraB. Mbeya, M. Rassool, L. Geiter, Y. L. Cho, N. Heinrich (Lead / Corresponding author)
Dive into the research topics of 'A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis'. Together they form a unique fingerprint.